StockData

Sinovac Biotech vs Zai Lab

SVA and ZLAB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How SVA and ZLAB compare

Sinovac Biotech grew revenue faster over the last twelve months (6.8% versus 5.1% for Zai Lab).

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricSVAZLAB
Size and price
Market cap–$36.5B
Share price$6.47$23.47
Change, 1 year0.00%8.0%
Change, 5 years0.00%−69.5%
Beta (5Y)0.001.46
Employees2,6021,784
StockData Score
Total score77
Valuation score00
Growth score2 (better)1
Performance score03 (better)
Health score5 (better)3
Dividend score00
Valuation
P/S–81.1×
P/B–60.0×
FCF yield–−0.38%
Fair value–$4.52
Margin of safety–−420%
Growth
Revenue growth (TTM)6.8% (better)5.1%
Revenue growth, 5Y average−5.4%56.5% (better)
EPS growth (TTM)−165%–
Profitability
Gross margin67.9% (better)56.5%
Operating margin−127%−58.7% (better)
Net margin–−41.9%
FCF margin−145%−31.0% (better)
Return on equity–−26.9%
Return on invested capital–−90.4%
Financial health
Debt / equity0.000.39 (better)
Interest coverage–−44.1×
Current ratio4.59 (better)2.13
Altman Z-score–43.35
Piotroski F-score–4
Dividends and buybacks
Years of dividend growth0–
Shareholder yield–0.00%
Ownership
Held by institutions14.6%2.8%
Held by insiders65.7%0.67%
Insider net buying, 12 months–−$10.7M
Short interest, % of float0.33%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.